How Testosterone Cypionate Affects Haemoglobin

Testosterone cypionate raises haemoglobin through the same erythropoietic pathways as any injectable testosterone ester, because the cypionate ester is cleaved before the hormone reaches any receptor:

1. EPO upregulation increases the marrow signal for red cell production.
2. Hepcidin suppression increases iron absorption and mobilisation from stores, supplying the iron needed for haem synthesis.
3. Direct erythroid progenitor stimulation at the bone marrow.

Why haemoglobin and haematocrit sometimes disagree: haematocrit is the proportion of blood volume occupied by red cells, so it is sensitive to plasma volume. Dehydration concentrates the sample and inflates haematocrit; overhydration or the plasma volume expansion that some men experience on testosterone can mask a genuine rise. Haemoglobin is a direct measurement of oxygen-carrying protein mass per volume and is somewhat less susceptible to this, which is why a haemoglobin above 18.5 g/dL alongside a haematocrit that looks acceptable is a meaningful finding rather than a lab error.

Cypionate versus enanthate: no difference. The ester is a delivery mechanism, not a pharmacology. Injection frequency and weekly dose determine peak concentration, and peak concentration determines the erythropoietic drive.

Replacement doses (100-200 mg/week):

• Haemoglobin typically rises 1 to 2 g/dL over the first 3 to 6 months
• A man starting at 15 g/dL commonly settles between 16 and 17 g/dL
• Haemoglobin above 18.5 g/dL warrants intervention

Supraphysiological doses (300-600+ mg/week):

• Rises of 2 to 3 g/dL or more are common
• Values of 18 to 19 g/dL are frequently seen and are not benign

Bhasin (2001, PMID 11701431) gave graded testosterone doses up to 600 mg/week for 20 weeks under GnRH agonist suppression and found haemoglobin changes positively correlated with testosterone concentration, consistent with a single linear dose-response relationship. There is no plateau dose above which haemoglobin stops responding.

Timing: The rise begins within 2 to 4 weeks and plateaus at 3 to 6 months, in step with haematocrit.

Reversibility: Haemoglobin falls back toward baseline over 2 to 3 months after stopping or after a substantial dose reduction.

Always run haemoglobin and haematocrit together. They are reported on the same full blood count and interpreting either alone loses information.

Baseline: Full blood count before starting.

First year: Every 3 months, at trough.

Stable patients: Every 6 months.

Sampling technique matters:

• Sample at trough, immediately before the next injection.
• Be normally hydrated. A dehydrated sample inflates haematocrit more than haemoglobin, and the discrepancy between the two is a clue that hydration, not erythropoiesis, explains the result.

Thresholds:

• Haemoglobin above 18.5 g/dL is the conventional point at which action is warranted, roughly corresponding to a haematocrit of 54%.
• A haemoglobin above 18.5 g/dL with a haematocrit below 54% should still be treated as a genuine finding.

The interventions are the same as for haematocrit:

• Increase injection frequency to lower peak testosterone concentrations
• Reduce weekly dose by 10 to 20%
• Therapeutic phlebotomy or blood donation
• Confirm hydration status before assuming the number is real

Track ferritin in parallel: Every unit of blood removed takes roughly 200 to 250 mg of iron with it. Men who donate repeatedly to control haemoglobin frequently end up iron deficient, and the resulting fatigue is often misread as inadequate testosterone dosing.

Do not switch esters as a strategy: Cypionate and enanthate produce the same haemoglobin response. Dose and frequency are the variables that matter.

Sleep apnoea: Untreated obstructive sleep apnoea raises haemoglobin independently and is common in the same demographic. If haemoglobin is climbing faster than the dose explains, this is worth investigating.

Further reading: TRT, haemoglobin and haematocrit